ライフサイエンスコーパス: exacerbation

1 initiated 14 (+/-3) days after an index COPD exacerbation.

2 ns and may serve as a biomarker of an asthma exacerbation.

3 might improve COPD management after a severe exacerbation.

4 icantly higher when patients exhibited acute exacerbation.

5 ng and systemic microangiopathy - in disease exacerbation.

6 ion included 53,654 participants with asthma exacerbation.

7 rity, and it improved after treatment for CF exacerbation.

8 o-infections, which often results in disease exacerbation.

9 with COPD who were recovering from a severe exacerbation.

10 ontribute to lung function decline and acute exacerbation.

11 ng factors to airway inflammation and asthma exacerbation.

12 pneumococcal infection-induced lung fibrosis exacerbation.

13 rbation compared to patients without disease exacerbation.

14 o design a prognostic algorithm to detect HF exacerbation.

15 mary outcome was the time to a severe asthma exacerbation.

16 after the diagnosis including the period of exacerbation.

17 ficantly improve the time to a severe asthma exacerbation.

18 8 years, of whom 160 had at least one severe exacerbation.

19 ed inflammation and be associated with acute exacerbation.

20 novel strategies to combat asthma or asthma exacerbation.

21 0 (19.3%) were classified as having frequent exacerbation.

22 %) in the placebo group had 1 or more severe exacerbations.

23 (IRR = 2.24; 95% CI [1.29-3.89]) respiratory exacerbations.

24 (IFN)-beta, during URTI, could prevent these exacerbations.

25 is strongly associated with childhood asthma exacerbations.

26 budesonide maintenance therapy in preventing exacerbations.

27 ients with symptomatic COPD and a history of exacerbations.

28 biologically relevant marker to predict COPD exacerbations.

29 s with severe asthma and those with frequent exacerbations.

30 (DEP), increases risk for asthma and asthma exacerbations.

31 associated with asthma severity and risk of exacerbations.

32 hma control, lung function, medications, and exacerbations.

33 ventional clinical measures as predictors of exacerbations.

34 promise as a biomarker of prospective asthma exacerbations.

35 flammation and ameliorate virus-induced COPD exacerbations.

36 for an objective biomarker to predict asthma exacerbations.

37 opulations in patients who experienced prior exacerbations.

38 increased type 2 inflammation drives asthma exacerbations.

39 in the placebo group experienced one or more exacerbations.

40 practices are crucial for the prevention of exacerbations.

41 , including FEV(1)% predicted and history of exacerbations.

42 onsequently might impact asthma symptoms and exacerbations.

43 ntravenous antibiotic use to treat pulmonary exacerbations.

44 chronic obstructive pulmonary disease (COPD) exacerbations.

45 s with COPD experiencing naturally occurring exacerbations.

46 ns (URTIs) are important triggers for asthma exacerbations.

47 asis at baseline and increase further during exacerbations.

48 hronic bronchitis, or to alleviate recurrent exacerbations.

49 e pulmonary disease (COPD) at risk of future exacerbations.

50 disease (COPD) is characterized by frequent exacerbations.

51 ut the genetic determinants of severe asthma exacerbations.

52 1) baseline characteristics, (2) respiratory exacerbations, (3) progression to COPD at 5 years, and (

53 fibrosis comprised 34% with idiopathic acute exacerbation (65%) being the most common admission type.

54 About 30% of asthma exacerbations admitted to the ICU do not resolve within

55 The disease in mice exhibits acute exacerbation after intrapulmonary instillation of corisi

56 n predicting either a worsening of asthma or exacerbation after LAIV using a regression model.

57 ations and one-year incidence of respiratory exacerbations after adjusting for age, sex, current smok

58 Thirty-three percent experienced asthma exacerbations after one guided BT compared with 73% afte

59 quent connectivity state, and temporary pain exacerbation alters connectivity between the VL/VPL and

60 Rhinovirus frequently causes asthma exacerbations among children and young adults who are al

61 ised C-reactive protein 14 days after a COPD exacerbation, an additional course of ciprofloxacin resu

62 ergency department (ED) with an acute asthma exacerbation and correlate these parameters with clinica

63 In six participants with CF exacerbation and follow-up after treatment, a decrease i

64 s with COPD who are recovering from a severe exacerbation and seems to negatively affect sleep qualit

65 y and secondary outcomes were, respectively, exacerbations and an increase in reliever prescriptions.

66 its expression levels correlated with asthma exacerbations and antiviral pathways.

67 o study medication at randomization.Methods: Exacerbations and change from baseline in trough FEV(1)

68 Viral infections are major drivers of exacerbations and clinical burden in patients with asthm

69 tial to identify children at higher risk for exacerbations and improve outcomes.

70 nical trials showing reductions in pulmonary exacerbations and improved FEV(1).

71 Dupilumab significantly reduced severe exacerbations and improved lung function and asthma cont

72 experimental rhinovirus (RV)-16-induced COPD exacerbations and its relationship to disease severity.

73 increasing symptoms in patients with asthma exacerbations and may serve as a biomarker of an asthma

74 tives: To test whether the long-term risk of exacerbations and mortality differs between these two su

75 hieve symptom control and reduce the risk of exacerbations and stepped down after a period of prolong

76 TRAP exposure on asthma development, asthma exacerbation, and/or airway inflammation and to determin

77 dices of severity, including symptom scores, exacerbations, and controller medication requirements, b

78 Ps in GSDMB associated with asthma severity, exacerbations, and GSDMB expression levels.

79 the potential immune pathophysiology of COPD exacerbations, and indicate that NK cell phenotyping may

80 ms, radiographic emphysema and gas trapping, exacerbations, and progression to COPD.

81 50-pack-year smoking history, frequent COPD exacerbations, and recurrent pneumonia.

82 asthma endotypes related to asthma severity, exacerbations, and responsiveness to corticosteroids and

83 th COPD and a history of severe and frequent exacerbations; and 6) a conditional recommendation for o

84 weight and lung function and fewer pulmonary exacerbations annually.

85 Asthma exacerbations are inflammatory events that rarely result

86 Chronic obstructive pulmonary disease (COPD) exacerbations are prone to nonrecovery, but there are no

87 Asthma exacerbations are triggered by rhinovirus infections.

88 ib treatment prolonged the time to the first exacerbation as compared with placebo (P = 0.03 for 10-m

89 ficantly worsened infection-induced fibrosis exacerbation as determined by increased lung collagen de

90 ited pneumococcal infection-induced fibrosis exacerbation as efficaciously as antibiotic treatment wh

91 were associated with markers of coagulation exacerbation as fibrinogen and D-dimers, and were increa

92 s56151658 were associated with severe asthma exacerbations at a P value of .01 or less in the same di

93 matter whether the patients had prior severe exacerbation before the index date, those receiving angi

94 o assess whether incompletely recovered COPD exacerbations benefit from additional treatment with cip

95 ses 2866 children experiencing severe asthma exacerbation between ages 2 and 6 years, and 65,415 non-

96 no difference with regard to risk of severe exacerbations between the two trajectories, but individu

97 otor variability can manifest not only as an exacerbation but also as a reduction relative to healthy

98 ent did not numerically reduce the number of exacerbations, but did attenuate URTI-induced worsening

99 3 years, allergic comorbidities, and disease exacerbation by the trigger factors stress, pollen expos

100 weeks) studies significantly reduced severe exacerbations by 55%-69%/57%-60% (all P<.05) and 53%-69%

101 Severe asthma exacerbations cause significant morbidity and costs.

102 options to decrease the severity of wheezing exacerbations caused by respiratory viral infections.

103 y increased in human IPF patients with acute exacerbation compared to patients without disease exacer

104 lls expressing CRTh2 and worse FEV(1) during exacerbation compared with the follow-up.

105 (UMEC)/vilanterol (VI) significantly reduced exacerbations compared with FF/VI or UMEC/VI in patients

106 lation-based birth cohort with severe wheeze exacerbations confirmed in healthcare records.

107 ictive biomarkers.Methods: Three-year asthma exacerbation data were analyzed in 406 adults in the Sev

108 In chronic schizophrenia patients with acute exacerbations, doses higher than the identified 95% effe

109 icrobiota, resulting in either disease onset/exacerbation due to a "poor" diet or protection against

110 entified two distinct trajectories of severe exacerbations during childhood with different early-life

111 The primary endpoint was severe exacerbations during treatment.

112 revious year, and suffered their next severe exacerbation earlier.Conclusions: Sleep-related neck-mus

113 henomenon that results in more frequent COPD exacerbation events, contributing to disease progression

114 e Monitoring for Prediction of Heart Failure Exacerbation) examined the performance of a personalized

115 tle understanding of immune function in COPD exacerbations exists.

116 " (n = 150, 93.7%) and "Early-onset frequent exacerbations (FE)" (n = 10, 6.3%).

117 Medications, exacerbations, FEV(1) (76% predicted vs 76% predicted; P

118 characterized by episodes of quiescence and exacerbation (flares).

119 worsening diarrhea and was diagnosed with CD exacerbation for which she was given ustekinumab.

120 magnetic resonance imaging as a predictor of exacerbation frequency following imaging.

121 for association with FEV(1) % predicted and exacerbation frequency.

122 h CRS for preventive interventions to reduce exacerbation frequency.

123 hma control and quality of life but not with exacerbation frequency.

124 r classifying subjects into high- versus low-exacerbation groups and then used statistical regression

125 rogression in bacterially triggered fibrosis exacerbation has not been explored so far.

126 However, patterns of severe exacerbations have not been studied.

127 iologics (already used for preventing asthma exacerbations) have the potential to circumvent steroid

128 in patients with COPD recovering from severe exacerbations (i.e., requiring hospitalization) and its

129 tories among these 160 children: "Infrequent exacerbations (IE)" (n = 150, 93.7%) and "Early-onset fr

130 00/300 mg every 2 weeks (q2w) reduced severe exacerbations, improved prebronchodilator (pre-BD) force

131 year (EPA) and 168 participants (41%) had no exacerbation in any year (exacerbation-resistant asthma)

132 lts: Eighty-three participants (21%) had >=1 exacerbation in each year (EPA) and 168 participants (41

133 infections in the susceptibility to disease exacerbation in response to a different secondary viral

134 95% CI, 11%-19.1%) reported a severe asthma exacerbation in the 4 weeks after immunization, requirin

135 The adjusted hazard ratio for exacerbation in the comparison of brensocatib with place

136 atients with COPD who experienced more acute exacerbation in the previous year.

137 of whom half had no reliever prescription or exacerbation in the year prior.

138 nformed probability increased to 63% with an exacerbation in Year 2 and 82% with an exacerbation in Y

139 The uninformed probability of an exacerbation in Year 3 was 40%, but the informed probabi

140 ess uninformed and informed probabilities of exacerbation in year 3.

141 th an exacerbation in Year 2 and 82% with an exacerbation in Years 1 and 2.

142 upplementation to improve the time to severe exacerbations in high-risk children with asthma aged 6 t

143 ]; moderate SOE), independent of severity of exacerbations in out- and inpatients.

144 a novel adjunctive treatment to limit acute exacerbations in patients with IPF.

145 genic link between skin disease and systemic exacerbations in SLE remains elusive.

146 those patients with a history of one or more exacerbations in the past year requiring antibiotics or

147 intolerance who have experienced one or more exacerbations in the past year; 3) a conditional recomme

148 py (ICS/LABA/LAMA) if the patient has had no exacerbations in the past year; 4) no recommendation for

149 with bronchiectasis who had had at least two exacerbations in the previous year to receive placebo, 1

150 d more disrupted sleep, had experienced more exacerbations in the previous year, and suffered their n

151 with EPA, and IL-6 and eosinophils predicted exacerbations in the sample as a whole.

152 m, 32-week trial in patients with >=2 asthma exacerbations in the year prior to enrollment, despite r

153 D3 supplementation to prevent severe asthma exacerbations in this group of patients.

154 rferon and PPRs in rhinovirus-induced asthma exacerbations in vivo are uncertain.

155 DP greater than 4.28% was associated with an exacerbation incidence rate ratio of 2.5 (95% CI = 1.3-4

156 d use, study site and clinical predictors of exacerbations, including FEV(1)% predicted and history o

157 rred in EPA, and the incident rate ratio for exacerbation increased 10% for each 1-pg/mul increase in

158 ot occur in EPA, the incident rate ratio for exacerbations increased 9% for each 100-cell/mul increas

159 Asthma with severe exacerbation is the most common cause of hospitalization

160 infections, wherein control of inflammatory exacerbations is a major therapeutic issue.

161 plementation reduces severe childhood asthma exacerbations is unclear.

162 sitis (CRS) is complicated by frequent acute exacerbations leading to significant health care burden

163 Despite the significance of exacerbations, little understanding of immune function i

164 od lasted 6 months to record the next severe exacerbation.Measurements and Main Results: Twenty-nine

165 AL, respiratory symptoms, and admissions for exacerbations.Measurements and Main Results: Haemophilus

166 ts impact on sleep quality and recurrence of exacerbations.Methods: Video polysomnography with neck-m

167 31 nonsevere asthma) and longitudinal asthma exacerbations (n = 273) was performed.

168 demonstrated a significant effect on asthma exacerbations.Objectives: The dynamics of exogenous IFN-

169 structive pulmonary disease and a history of exacerbations.Objectives: To understand whether inhaled

170 nificantly associated with acute respiratory exacerbation (odds ratio = 1.81; 95% confidence interval

171 atic ductal adenocarcinoma (PDAC) results in exacerbation of a fibro-inflammatory microenvironment th

172 mmation, ST2(+) myeloid cells contributed to exacerbation of airway inflammation, suggesting the impo

173 rences in sputum microbial profiles at acute exacerbation of airways disease are reflected by the gam

174 (2020) observed an exacerbation of alpha-syn pathology in the presence of A

175 many variables influence the development and exacerbation of anemia, one major contributing factor is

176 r, our study indicates that RSV prevents the exacerbation of atherosclerosis induced periodontitis by

177 anatomic conditions, such as development and exacerbation of bony dehiscence or fenestration defects,

178 Community-acquired pneumonia (CAP) and acute exacerbation of chronic obstructive pulmonary disease (A

179 initiating pulmonary rehabilitation after an exacerbation of chronic obstructive pulmonary disease (C

180 status, with the original concern focused on exacerbation of clinical effects of vitamin B-12 deficie

181 nt amplification include coverage biases and exacerbation of contamination.

182 atment failure in adults with mild to severe exacerbation of COPD.

183 The role of T cells in the resolution or exacerbation of COVID-19, as well as their potential to

184 nical factors associated with frequent acute exacerbation of CRS (AECRS).

185 is-mediated intestinal barrier breakdown and exacerbation of disease during inflammatory arthritis in

186 mmensal species unexpectedly associated with exacerbation of EAE in a genetically susceptible host, w

187 vering whale populations, contributed to the exacerbation of entanglements throughout the marine heat

188 were no improvements in muscle strength and exacerbation of exercise intolerance concomitant with fu

189 gnaling directly modulates MMC9 function and exacerbation of experimental IgE-mediated food allergic

190 and cell-to-cell transfer, and abrogates the exacerbation of HIV-1 infection induced by Mtb.

191 otein O-GlcNAcylation, which permits limited exacerbation of inflammation upon macrophage activation.

192 however, it may also be associated with the exacerbation of injury and development of chronic diseas

193 Rbeta, we observed dramatic, female-specific exacerbation of intestinal inflammation accompanied by s

194 ute worsening of their disease, termed acute exacerbation of IPF, which may be caused by bacterial an

195 teria shedding corisin are involved in acute exacerbation of IPF, yielding insights to the molecular

196 ingivalis-mediated gut barrier breakdown and exacerbation of joint inflammation during inflammatory a

197 s "silencers," suppressing infection-induced exacerbation of lung fibrosis in mice, and their expansi

198 DA neurons, including those of inflammatory exacerbation of neurodegeneration, is a major impediment

199 blem, but published literature regarding the exacerbation of physical IPV during the coronavirus dise

200 ) T cells by cross-priming DC contributes to exacerbation of postischemic inflammatory damage of the

201 -week trial involving patients with an acute exacerbation of schizophrenia, SEP-363856, a non-D2-rece

202 safety of SEP-363856 in adults with an acute exacerbation of schizophrenia.

203 In multiple sclerosis, exacerbation of symptoms with rising body temperature is

204 over the lifespan in mice, acceleration and exacerbation of that dysfunction with WD consumption, th

205 tes (P < 0.0033) and were associated with an exacerbation of the genetic risk of FG and HbA(1c) (P (I

206 on, and alveolar bone loss through sustained exacerbation of the host response.

207 hibitors provides another avenue to halt the exacerbation of the inflammatory response in periodontal

208 ost-exertional malaise (PEM), defined as the exacerbation of the patient's symptoms following minimal

209 ionally decimated, with evidence pointing to exacerbation of underlying graft-versus-host disease (GV

210 Respiratory syncytial virus (RSV) causes exacerbations of asthma and preschool wheeze (PSW).

211 is involved in both the onset and the acute exacerbations of asthma.

212 associated with increased risk of pulmonary exacerbations of CF.

213 habilitation (PR) after hospitalizations for exacerbations of chronic obstructive pulmonary disease (

214 jor cause of common cold, bronchiolitis, and exacerbations of chronic pulmonary diseases such as asth

215 From 2001 until 2018, we observed 139 severe exacerbations of COPD and 215 deaths, of which 55 were d

216 ntibody as a strategy to abrogate the severe exacerbations of dry eye disease observed in aged mice.

217 This severe phenotype resembled acute exacerbations of generalised pustular psoriasis (GPP), a

218 n cause pneumonia and sepsis and can trigger exacerbations of lung diseases.

219 We specifically examined associations with exacerbations of suspected viral and/or bacterial, or no

220 al, because it can reduce the risk of future exacerbations of the disease at the expense of increasin

221 opment of asthma and COPD later in life, and exacerbations of these diseases correlate with the prese

222 eractivity, including erythema, peeling, and exacerbation on water exposure.

223 s whether stepping down medication increased exacerbations or reliever use, as well as its impact on

224 correlated with asthma and greater number of exacerbations (P < .05).

225 (odds ratio, >1.25) and longitudinal asthma exacerbations (P < .05).

226 SDMB expression, asthma severity, and asthma exacerbations (P < .05).

227 sification system (P = .0015), more frequent exacerbations (P = .0042), blood eosinophil level less t

228 produce sputum during "stable" or pulmonary "exacerbation" periods and had complete pairs of EDC and

229 During exacerbation, peripheral blood Th2 cell numbers correlat

230 The time to the first exacerbation (primary end point), the rate of exacerbati

231 ciprofloxacin for incompletely resolved COPD exacerbations prolonged the time until the next event.Ob

232 ationale: Cross-sectional studies suggest an exacerbation-prone asthma (EPA) phenotype and the utilit

233 Exacerbation-prone asthma subtype has been reported in s

234 duce the annual on-treatment moderate/severe exacerbation rate (19%; P < 0.001) compared with UMEC/VI

235 ificantly reduced the annual moderate/severe exacerbation rate compared with UMEC/VI in prior ICS use

236 A non-significant trend in annual asthma exacerbation rate reduction favouring benralizumab over

237 A trend in annual asthma exacerbation rate reduction favouring benralizumab over

238 osage reduction, OCS elimination, and annual exacerbation rate reduction.

239 Numerically, AZD9412 did not reduce severe exacerbation rate, ACQ-6, asthma symptom scores or relie

240 tients that was expected and, due to the low exacerbation rate, the trial was stopped early.

241 terminated early due to an unexpectedly low exacerbation rate.

242 ic oxide [FeNO] >=25 ppb), annualized severe exacerbation rates over the treatment period, changes fr

243 VI compared with UMEC/VI was seen for severe exacerbation rates, regardless of prior ICS use (prior I

244 taking amantadine, and a multiple sclerosis exacerbation requiring hospital admission while taking m

245 pants (41%) had no exacerbation in any year (exacerbation-resistant asthma).

246 Compared with exacerbation-resistant asthma, EPA was characterized by

247 3 to 14 days were associated with increased exacerbation resolution at the end of the intervention (

248 nes whose expression is predictive of asthma exacerbations revealed a novel association of a regulato

249 Serum IL-6 was associated with asthma exacerbation risk but not with symptoms or lung function

250 There was no increased exacerbation risk for each possible medication stepdown

251 ores that correlate to clinical severity and exacerbation risk in adult patients with CF.Supplemental

252 plementary quantitative marker of individual exacerbation risk that is useful for monitoring individu

253 iron conveying a 24% and 2-fold increase in exacerbation risk, respectively.

254 in quality-of-life impairment and increased exacerbation risk.

255 levels in the subsequent year had increased exacerbation risk.

256 hways does not eradicate asthma symptoms and exacerbation risk; further work is needed to clarify und

257 xacerbation (primary end point), the rate of exacerbations (secondary end point), sputum neutrophil e

258 chronic obstructive pulmonary disease/asthma exacerbation, septicemia, acute respiratory failure, and

259 al inflammation, nor whether this relates to exacerbation severity.

260 pollen exposure and early markers of asthma exacerbations such as lung function changes and increase

261 ical phenotypes of COPD, including increased exacerbation susceptibility, is unknown.

262 COPD is frequently punctuated by acute exacerbations that are precipitated primarily by infecti

263 Patients with bronchiectasis have frequent exacerbations that are thought to be related to neutroph

264 included the time to a viral-induced severe exacerbation, the proportion of participants in whom the

265 y improve the time to a viral-induced severe exacerbation, the proportion of participants whose dose

266 t significantly improve the time to a severe exacerbation: the mean time to exacerbation was 240 days

267 s further found to be sufficient for disease exacerbation thus confirming a major role for macrophage

268 ortality among patients admitted with asthma exacerbation to the ICU.Methods: We performed a retrospe

269 ate correlation with the number of pulmonary exacerbations to occur in the 12 months after the CT exa

270 ed longitudinal k-means clustering to derive exacerbation trajectories among 887 participants from a

271 del provided the optimal solution for severe exacerbation trajectories among these 160 children: "Inf

272 We then compared children in the two exacerbation trajectories with those who have never whee

273 Participants with CF exacerbation underwent repeat MRI after their treatment

274 ANTS: The Vitamin D to Prevent Severe Asthma Exacerbations (VDKA) Study was a randomized, double-blin

275 ater than 4.28% (n = 32) had a median of 1.5 exacerbations versus 0.0 for subjects with a VDP less th

276 h DNA and RNA is thought to initiate disease exacerbation via plasmacytoid dendritic cells.

277 e to a severe exacerbation: the mean time to exacerbation was 240 days in the vitamin D3 group vs 253

278 The median time to the next exacerbation was 32.5 days (interquartile range 13-50) i

279 The 25th percentile of the time to the first exacerbation was 67 days in the placebo group, 134 days

280 s: Noninvasive ventilation use during asthma exacerbation was associated with improved outcomes but s

281 all, opioid exposure in the 7 days before an exacerbation was significantly associated with acute res

282 Time to first exacerbation was significantly prolonged with inhaled an

283 of a Year 3 exacerbation with no Year 1 or 2 exacerbations was 13%.

284 0 mum in aerodynamic diameter with infective exacerbations was also evident and supported by a daily

285 Exacerbations were also analyzed while excluding data fr

286 Participants hospitalized with COPD exacerbations were assigned 1:1 to receive either usual

287 n 1 second (FEV(1)), and risk of respiratory exacerbations were evaluated in the test cohort (center

288 Exacerbations were modelled using a zero-inflated negati

289 s, during a period of disease stability, and exacerbations were recorded prospectively over the follo

290 dults presenting to the ED with acute asthma exacerbations were recruited after giving informed conse

291 detect precursors of hospitalization for HF exacerbation with 76% to 88% sensitivity and 85% specifi

292 , 21 of 30 patients (70%) developed headache exacerbation with migraine-like features after CGRP, com

293 mes: (1) difference in incidence of headache exacerbation with migraine-like features and (2) differe

294 The probability of a Year 3 exacerbation with no Year 1 or 2 exacerbations was 13%.

295 model to predict patients with a history of exacerbations with high sensitivity and specificity.

296 means of support until the resolution of the exacerbation, with an acceptably low rate of complicatio

297 n were elevated in participants who had COPD exacerbations, with a 2-fold increase in BALF ferritin a

298 unmet needs surrounding ICU-admitted asthma exacerbations, with a focus on currently available drugs

299 The primary outcome was the time to the next exacerbation within a 90-day period.Measurements and Mai

300 , n = 389) or have wheezed but had no severe exacerbations (WNE, n = 338).